Innovent and Eli Lilly Report NMPA's Acceptance of NDA for IBI301 (rituximab- biosimilar) for Non-Hodgkin's lymphoma
Shots:
- The NDA is based on two P-III studies evaluating the safety- efficacy & PK of IBI301 vs MabThera/Rituxan (rituximab) in patients with DLBCL & CD20-positive B-cell lymphoma respectively
- The two P-III studies resulting in meeting its 1EPs demonstrating the bio-similarity b/w IBI301 and branded rituximab
- IBI301 is a biosimilar of rituximab targeting CD20 antigen on the surface of B lymphocytes and mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC)- co-developed by Lilly and Innovent for NHL and other diseases
Click here to read full press release/ article
Ref: Innovent | Image: Eli Lilly
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com